Hairy cell leukemia

References

Key articles

Parry-Jones N, Joshi A, Forconi F, et al. Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V). Br J Haematol. 2020 Dec;191(5):730-7.Full text  Abstract

Foucar K, Falini B, Catovsky D, et al. Hairy cell leukemia. In: WHO classification of tumours of haematopoietic and lymphoid tissues, vol 2, 4th ed. Geneva, Switzerland: World Health Organization Press; 2008:188-90.

Robak T, Matutes E, Catovsky D, et al. Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(suppl 5):v100-7.Full text  Abstract

Gidron A, Tallman MS. Hairy cell leukemia: towards a curative strategy. Hematol Oncol Clin North Am. 2006 Oct;20(5):1153-62. Abstract

Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000 Nov 1;96(9):2981-6.Full text  Abstract

Reference articles

1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375-90.Full text  Abstract

2. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016 Nov 12;66(6):443-59.Full text  Abstract

3. Staines A, Cartwright RA. Hairy cell leukaemia: descriptive epidemiology and a case-control study. Br J Haematol. 1993 Dec;85(4):714-7. Abstract

4. Tadmor T, Polliack A. Epidemiology and environmental risk in hairy cell leukemia. Best Pract Res Clin Haematol. 2015 Dec;28(4):175-9. Abstract

5. Monnereau A, Slager SL, Hughes AM, et al. Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014 Aug;2014(48):115-24.Full text  Abstract

6. Nordström M, Hardell L, Magnuson A, et al. Occupational exposures, animal exposure and smoking as risk factors for hairy cell leukaemia evaluated in a case-control study. Br J Cancer. 1998 Jun;77(11):2048-52. Abstract

7. Orsi L, Delabre L, Monnereau A, et al. Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case-control study. Occup Environ Med. 2009 May;66(5):291-8. Abstract

8. Paillassa J, Cornet E, Noel S, et al. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer J. 2020 May 27;10(5):62.Full text  Abstract

9. Parry-Jones N, Joshi A, Forconi F, et al. Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V). Br J Haematol. 2020 Dec;191(5):730-7.Full text  Abstract

10. Oleske D, Golomb HM, Farber MD, Levy PS. A case-control inquiry into the etiology of hairy cell leukemia. Am J Epidemiol. 1985 May;121(5):675-83. Abstract

11. Stewart DJ, Keating MJ. Radiation exposure as a possible etiologic factor in hairy cell leukemia (leukemic reticuloendotheliosis). Cancer. 1980 Oct 1;46(7):1577-80. Abstract

12. Wolf BC, Martin AW, Neiman RS, et al. The detection of Epstein-Barr virus in hairy cell leukemia cells by in situ hybridization. Am J Pathol. 1990 Mar;136(3):717-23. Abstract

13. Colovic MD, Jankovic GM, Wiernik PH. Hairy cell leukemia in first cousins and review of the literature. Eur J Haematol. 2001 Sep;67(3):185-8. Abstract

14. Cawley JC. The pathophysiology of the hairy cell. Hematol Oncol Clin North Am. 2006 Oct;20(5):1011-21. Abstract

15. Burthem J, Cawley JC. The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells. Blood. 1994 Jan 15;83(2):497-504.Full text  Abstract

16. Maitre E, Cornet E, Troussard X. Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019 Dec;94(12):1413-22.Full text  Abstract

17. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011 Jun 16;364(24):2305-15.Full text  Abstract

18. Yam LT, Li CY, Lam KW. Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. N Engl J Med. 1971 Feb 18;284(7):357-60. Abstract

19. Forconi F, Sahota SS, Raspadori D, et al. Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. Blood. 2001 Aug 15;98(4):1174-81.Full text  Abstract

20. Forconi F, Sahota SS, Raspadori D, et al. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. Blood. 2004 Nov 15;104(10):3312-7.Full text  Abstract

21. Foucar K, Falini B, Catovsky D, et al. Hairy cell leukemia. In: WHO classification of tumours of haematopoietic and lymphoid tissues, vol 2, 4th ed. Geneva, Switzerland: World Health Organization Press; 2008:188-90.

22. Konig EA, Kusser WC, Day C, et al. p53 mutations in hairy cell leukemia. Leukemia. 2000 Apr;14(4):706-11. Abstract

23. Zuzel M, Cawley JC. The biology of hairy cells. Best Pract Res Clin Haematol. 2003 Mar;16(1):1-13. Abstract

24. Itamura H, Ide M, Sato A, et al. Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method. Int J Hematol. 2018 Oct;108(4):416-22. Abstract

25. Gini Ehungu JL, Mufuta JP, Ngiyulu RM, et al. A rare occurrence of hairy cell leukemia in a congolese child: a presentation and challenge of diagnosis in low resource settings. J Pediatr Hematol Oncol. 2013 Nov;35(8):e350-2. Abstract

26. Ward FT, Baker J, Krishnan J, et al. Hairy cell leukemia in two siblings. A human leukocyte antigen-linked disease? Cancer. 1990 Jan 15;65(2):319-21. Abstract

27. Rumi E, Passamonti F, Zibellini S, et al. HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia. Leuk Lymphoma. 2007 Apr;48(4):805-7. Abstract

28. Villemagne B, Bay JO, Tournilhac O, et al. Two new cases of familial hairy cell leukemia associated with HLA haplotypes A2, B7, Bw4, Bw6. Leuk Lymphoma. 2005 Feb;46(2):243-5. Abstract

29. Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017 Feb 2;129(5):553-60.Full text  Abstract

30. Flandrin G, Sigaux F, Sebahoun G, et al. Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol. 1984 Dec;11(4 suppl 2):458-71. Abstract

31. Yonal-Hindilerden I, Hindilerden F, Bulut-Dereli S, et al. Hairy cell leukemia presenting with isolated skeletal involvement successfully treated by radiation therapy and cladribine: a case report and review of the literature. Case Rep Hematol. 2015;2015:803921.Full text  Abstract

32. Hoffman MA. Clinical presentations and complications of hairy cell leukemia. Hematol Oncol Clin North Am. 2006 Oct;20(5):1065-73. Abstract

33. Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med. 1978 Nov;89(5 Pt 1):677-83. Abstract

34. Sharpe RW, Bethel KJ. Hairy cell leukemia: diagnostic pathology. Hematol Oncol Clin North Am. 2006 Oct;20(5):1023-49. Abstract

35. Hakimian D, Tallman MS, Hogan DK, et al. Prospective evaluation of internal adenopathy in a cohort of 43 patients with hairy cell leukemia. J Clin Oncol. 1994 Feb;12(2):268-72. Abstract

36. Tallman MS, Hakimian D, Peterson LC. Hairy Cell Leukemia. Clinical oncology. 3rd ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2004:2564-78.

37. Kraut EH, Neff JC, Bouroncle BA, et al. Immunosuppressive effects of pentostatin. J Clin Oncol. 1990 May;8(5):848-55. Abstract

38. Mercieca J, Matutes E, Moskovic E, et al. Massive abdominal lymphadenopathy in hairy cell leukaemia: a report of 12 cases. Br J Haematol. 1992 Nov;82(3):547-54. Abstract

39. Kraut EH. Clinical manifestations and infectious complications of hairy-cell leukaemia. Best Pract Res Clin Haematol. 2003 Mar;16(1):33-40. Abstract

40. Robbins BA, Ellison DJ, Spinosa JC, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood. 1993 Aug 15;82(4):1277-87.Full text  Abstract

41. Matutes E. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin North Am. 2006 Oct;20(5):1051-63. Abstract

42. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hairy cell leukemia [internet publication].Full text

43. Robak T, Matutes E, Catovsky D, et al. Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(suppl 5):v100-7.Full text  Abstract

44. Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma. 2011 Jun;52(suppl 2):21-4. Abstract

45. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009 Jun;145(6):733-40. Abstract

46. Sigal DS, Sharpe R, Burian C, et al. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood. 2010 Mar 11;115(10):1893-6.Full text  Abstract

47. Cornet E, Tomowiak C, Tanguy-Schmidt A, et al. Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. Br J Haematol. 2014 Aug;166(3):390-400.Full text  Abstract

48. Grever MR. How I treat hairy cell leukemia. Blood. 2010 Jan 7;115(1):21-8.Full text  Abstract

49. Grever MR, Lozanski G. Modern strategies for hairy cell leukemia. J Clin Oncol. 2011 Feb 10;29(5):583-90. Abstract

50. Medicines and Healthcare products Regulatory Agency. Cladribine (Litak, Leustat) for leukaemia: reports of progressive multifocal encephalopathy (PML); stop treatment if PML suspected. Dec 2017 [internet publication].Full text

51. Chihara D, Kantarjian H, O'Brien S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016 Sep;174(5):760-6.Full text  Abstract

52. Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia. J Clin Oncol. 2020 May 10;38(14):1527-38.Full text  Abstract

53. Maevis V, Mey U, Schmidt-Wolf G, et al. Hairy cell leukemia: short review, today's recommendations and outlook. Blood Cancer J. 2014 Feb 14;4:e184.Full text  Abstract

54. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005 Jul 1;106(1):241-6.Full text  Abstract

55. Goodman GR, Bethel KJ, Saven A. Hairy cell leukemia: an update. Curr Opin Hematol. 2003 Jul;10(4):258-66. Abstract

56. Gidron A, Tallman MS. Hairy cell leukemia: towards a curative strategy. Hematol Oncol Clin North Am. 2006 Oct;20(5):1153-62. Abstract

57. Else M, Dearden CE, Matutes E, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma. 2011 Jun;52(suppl 2):75-8. Abstract

58. Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018 Aug;32(8):1768-77.Full text  Abstract

59. Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021 Feb 24;14(1):35.Full text  Abstract

60. Tiacci E, Park JH, De Carolis L, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015 Oct 29;373(18):1733-47.Full text  Abstract

61. Dietrich S, Hüllein J, Hundemer M, et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol. 2013 Jul 1;31(19):e300-3.Full text  Abstract

62. Follows GA, Sims H, Bloxham DM, et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol. 2013 Apr;161(1):150-3.Full text  Abstract

63. Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol. 2013 Jul 10;31(20):e351-2.Full text  Abstract

64. Peyrade F, Re D, Ginet C, et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica. 2013 Feb;98(2):e20-2.Full text  Abstract

65. Samuel J, Macip S, Dyer MJ. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med. 2014 Jan 16;370(3):286-8.Full text  Abstract

66. Urnova ES, Al'-Radi LS, Kuz'mina LA, et al. Successful use of vemurafenib in a patient with resistant hairy cell leukemia [in Russian]. Ter Arkh. 2013;85(7):76-8. Abstract

67. Tiacci E, De Carolis L, Simonetti E, et al. Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia. N Engl J Med. 2021 May 13;384(19):1810-23.Full text  Abstract

68. Rogers KA, Andritsos LA, Wei L, et al. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood. 2021 Jun 24;137(25):3473-83. Abstract

69. BCSH Blood Transfusion Task Force. Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfus Med. 1996 Sep;6(3):261-71. Abstract

70. Jones G, Parry-Jones N, Wilkins B, et al. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol. 2012 Jan;156(2):186-95.Full text  Abstract

71. Park JH, Tallman MS. Left behind: should minimal residual disease be treated in hairy cell leukemia? Leuk Lymphoma. 2014 May;55(5):971-2.Full text  Abstract

72. Shurin SB. The spleen and its disorders. In: Hoffman R, ed. Hematology: basic principles and practice. 4th ed. Philadelphia, PA: Churchill Livingstone; 2005:901-9.

73. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36. Abstract

74. ClinicalTrials.gov. LMB-2 to treat hairy cell leukemia. NCT00321555. May 2021 [internet publication].Full text

75. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007 May 1;109(9):3672-5.Full text  Abstract

76. Goodman GR, Burian C, Koziol JA, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003 Mar 1;21(5):891-6. Abstract

77. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000 Nov 1;96(9):2981-6.Full text  Abstract

78. Saven A, Burian C, Adusumalli J, et al. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood. 1999 Apr 15;93(8):2471-7.Full text  Abstract

79. Belani R, Saven A. Cladribine in hairy cell leukemia. Hematol Oncol Clin North Am. 2006 Oct;20(5):1109-23. Abstract

80. Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections. Blood. 1992 Feb 15;79(4):888-94.Full text  Abstract

81. Goodman ER, Fiedor PS, Fein S, et al. Fludarabine phosphate and 2-chlorodeoxyadenosine: immunosuppressive DNA synthesis inhibitors with potential application in islet allo- and xenotransplantation. Transplant Proc. 1995 Dec;27(6):3293-4. Abstract

82. Perry MC. The chemotherapy source book. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.

83. Hisada M, Chen BE, Jaffe ES, et al. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst. 2007 Feb 7;99(3):215-22.Full text  Abstract

Use of this content is subject to our disclaimer